Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04686786




Registration number
NCT04686786
Ethics application status
Date submitted
23/12/2020
Date registered
29/12/2020
Date last updated
26/02/2024

Titles & IDs
Public title
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
Scientific title
A 57-Week, Multicenter, Active-treatment, Open-label Extension Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizures
Secondary ID [1] 0 0
2019-004057-83
Secondary ID [2] 0 0
CVL-865-SZ-002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Seizures 0 0
Condition category
Condition code
Neurological 0 0 0 0
Epilepsy
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CVL-865

Experimental: CVL-865 25 mg - Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Week 57 during the treatment period.


Treatment: Drugs: CVL-865
Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Treatment Emergent Adverse Event (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Timepoint [1] 0 0
From first dose of study drug up to Week 61 (follow up period)
Primary outcome [2] 0 0
Number of Participants with Clinically Significant Changes in Electrocardiogram (ECGs)
Timepoint [2] 0 0
Baseline up to Week 57 or early termination (ET)
Primary outcome [3] 0 0
Number of Participants with Clinically Significant Changes in Vital Sign Measurements
Timepoint [3] 0 0
Baseline up to Week 57 or early termination (ET)
Primary outcome [4] 0 0
Number of Participants with Clinically Significant Changes in Physical and Neurological Examination Results
Timepoint [4] 0 0
Baseline up to Week 57 or early termination (ET)
Primary outcome [5] 0 0
Number of Participants With Positive Response to Columbia Suicide-Severity Rating Scale (C-SSRS)
Timepoint [5] 0 0
Baseline up to Week 61 (follow up period)
Primary outcome [6] 0 0
Number of Participants with Positive Response to Modified Clinical Institute Withdrawal Assessment - Benzodiazepines (mCIWA-B)
Timepoint [6] 0 0
Week 54 up to Week 61

Eligibility
Key inclusion criteria
- Participants who completed treatment in Trial CVL-865-SZ-001 (NCT04244175)

- A female participant of childbearing potential who is sexually active with a
nonsterilized male partner must agree to use a highly effective method of
contraception from signing of informed consent through 30 days post last dose

- A male participant with a pregnant or a nonpregnant partner of childbearing potential
must agree to use a condom during treatment and until the end of relevant systemic
exposure in the male participant for 94 days following the last dose with the
investigational medicinal product (IMP)

- Participants who are capable of giving signed informed consent

- Participants who are able, in the opinion of the investigator, to understand the
nature of the trial and comply with protocol requirements, including the prescribed
dosage regimens, scheduled visits, laboratory tests, and other trial procedures
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participants who, in the opinion of the investigator, medical monitor, or sponsor,
should not participate in the trial

- Participants who, in the judgment of the investigator, experienced poor tolerability
to the IMP during the double-blind trial or whose safety assessments resulted in new
concerns that would suggest that the participant may not be appropriate for 57 weeks
of treatment with CVL-865 in an extension trial

- Participants who experienced status epilepticus during Trial CVL-865-SZ-001

- Participants who have demonstrated substantial noncompliance to trial procedures in
Trial CVL-865-SZ-001, based on the investigator's judgment, would not be eligible for
this trial

- Participants who answer "yes" on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active
Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal
Ideation with Specific Plan and Intent), or participants who answer "yes" on any of
the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted
attempt, preparatory acts, or behavior), or participants who, in the opinion of the
investigator, present a serious risk of suicide

- Participants with any of the following abnormalities in clinical laboratory tests at
Visit 1, as assessed by the central laboratory and confirmed by a single repeat
measurement, if deemed necessary (Females: Hemoglobin <11 gram per deciliter (g/dL);
Males: hemoglobin <12 g/dL; White blood cell (WBC) count <3.0 x 10 power 9 per liter
(10^9/L); Neutrophil count <2.0 x 10^9/L; Platelet count <150 × 10^9/L)

- Participants who would be likely to require the use of prohibited concomitant
medications during the trial

- Female participants who have a positive pregnancy test result

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/12/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2025
Actual
Sample size
Target
120
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Camperdown, New South Wales - Camperdown
Recruitment hospital [2] 0 0
Randwick, New South Wales - Randwick
Recruitment hospital [3] 0 0
Westmead, New South Wales - Westmead
Recruitment hospital [4] 0 0
Herston, Queensland - Herston
Recruitment hospital [5] 0 0
Fitzroy, Victoria - Fitzroy
Recruitment hospital [6] 0 0
Heidelberg, Victoria - Heidelberg
Recruitment hospital [7] 0 0
Melbourne, Victoria - Melbourne
Recruitment hospital [8] 0 0
Parkville, Victoria - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
3004 - Melbourne
Recruitment postcode(s) [8] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Connecticut
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Hawaii
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Maine
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oklahoma
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Utah
Country [17] 0 0
Poland
State/province [17] 0 0
Kujawsko-Pomorskie
Country [18] 0 0
Poland
State/province [18] 0 0
Pomorskie
Country [19] 0 0
Poland
State/province [19] 0 0
Wojnicz Lskie
Country [20] 0 0
Spain
State/province [20] 0 0
Andalusia
Country [21] 0 0
Spain
State/province [21] 0 0
Catalonia
Country [22] 0 0
Spain
State/province [22] 0 0
Madrid
Country [23] 0 0
Spain
State/province [23] 0 0
Sevilla
Country [24] 0 0
Spain
State/province [24] 0 0
Valencia
Country [25] 0 0
Ukraine
State/province [25] 0 0
Uzhgorod
Country [26] 0 0
Ukraine
State/province [26] 0 0
Lviv

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Cerevel Therapeutics, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as
adjunctive therapy in participants with focal onset seizures.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04686786
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Eliza Hueda
Address 0 0
Cerevel Therapeutics, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04686786